Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report


Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.

Aim(s): The optimal regimen for second and subsequent lines of chemotherapy for the treatment of SNECs remains unknown.

Materials and methods: This report describes a 50-year-old male patient with advanced sinonasal large-cell NEC (LCNEC) was treated with albumin-bound paclitaxel-based (nab-paclitaxel) regimens every 3 weeks as third-line chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Qi Z, Zhang Y, Li Y, Wang C, Wang X,

Keywords: neuroendocrine carcinoma, albumin-bound paclitaxe,

To read the full abstract, please log into your ENETS Member account.